On December 18, Jimin Credit Group announced that the Class 2.2 and Class 2.4 new drug JMX-2005 injections declared by the company have been approved by the China Drug Administration for clinical trials. This drug is intended to improve ischemic symptoms such as resting pain and ulcers due to peripheral artery disease.

On December 18, Jimin Credit Group announced that the Class 2.2 and Class 2.4 new drug JMX-2005 injections declared by the company have been approved by the China Drug Administration for clinical trials. This drug is intended to improve ischemic symptoms such as resting pain and ulcers due to peripheral artery disease.